Latest studies
- RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaSaudi Arabia - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaSaudi Arabia - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Saudi Arabia - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyIgANSaudi Arabia - Recruiting
Pompe Disease Registry Protocol
This registry tracks people with Pompe disease globally. It helps us understand the condition better, how it changes over time, and the effects of treatments. The goal is to improve care for everyone with Pompe disease.
Glycogen Storage Disease Type IIPompe DiseaseSaudi Arabia - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCSaudi Arabia - Recruiting
Fabry Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Fabry disease over time, including pregnant women. It helps doctors better understand the disease and improve care, without giving any new treatments. It's about observing, not experimenting.
Fabry DiseaseSaudi Arabia - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
Heart FailureSaudi Arabia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseSaudi Arabia - RecruitingPHASE3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This study is looking into a new medication, rilzabrutinib, for adults with a condition called IgG4-related disease. It compares the medication to a dummy pill to see if it's safe and helps control the disease over 52 weeks.
Immunoglobulin G4 Related DiseaseSaudi Arabia - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaSaudi Arabia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
Locally Advanced or Metastatic Breast CancerSaudi Arabia - Active not recruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaSaudi Arabia - RecruitingPHASE4
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
This study looks at a new treatment called dupilumab for people aged 40-85 with a severe lung condition called COPD. It aims to see if the treatment reduces lung inflammation and improves breathing and quality of life.
Chronic Obstructive Pulmonary DiseaseSaudi Arabia - RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory FailureSaudi Arabia - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
Breast Cancer; HER2-positive; MetastaticSaudi Arabia - RecruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisSaudi Arabia - Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Gaucher disease over time, whether or not they are receiving treatment. There's also a sub-study for pregnant women with Gaucher disease to see how their pregnancies and babies' health progress. It helps doctors learn more about the condition.
Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency DiseaseGlucosylceramide Beta-Glucosidase Deficiency DiseaseSaudi Arabia - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
Triple Negative Breast NeoplasmsSaudi Arabia - RecruitingPHASE2, PHASE3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
This study is looking at a new medicine called vericiguat for children and young people aged 29 days to 17 years with heart failure. We want to see if it can improve their heart health compared to a dummy medicine.
Heart FailureLeft Ventricular Systolic DysfunctionSaudi Arabia - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaSaudi Arabia - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
This study is comparing a new medication called remibrutinib with an existing treatment, teriflunomide, for people with relapsing multiple sclerosis (RMS). It aims to see how well remibrutinib works and if it's safe to use in managing RMS symptoms.
Relapsing Multiple SclerosisSaudi Arabia - RecruitingPHASE3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
This study looks at a new drug, Dostarlimab, for adults with a certain type of head and neck cancer. It compares Dostarlimab to a dummy drug (placebo) after standard chemo and radiation, to see if it's safe and effective.
Neoplasms, Head and NeckSaudi Arabia - Active not recruitingPHASE3
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
This study looks at a drug called abemaciclib, given with standard hormone therapy after surgery for a type of breast cancer. We want to see if it's safe and helps stop the cancer coming back in people with certain high-risk breast cancers.
Breast CancerSaudi Arabia - RecruitingPHASE3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This study looks at new treatments for heart failure and kidney problems. Researchers are testing two different doses of a new drug combination against an existing medication to see if they can improve heart health and reduce hospital stays.
Heart Failure and Impaired Kidney FunctionSaudi Arabia - RecruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
Metabolic Dysfunction Associated SteatohepatitisSaudi Arabia - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesSaudi Arabia - RecruitingPHASE3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
This study is looking into a new medication called Elecoglipron for weight management. It's for adults who are overweight or have obesity, with or without Type 2 diabetes, to see if it helps them lose weight safely when combined with diet and exercise.
Weight ManagementSaudi Arabia - Active not recruitingPHASE3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
This study is testing a new medicine, povetacicept, for adults with a kidney condition called IgA Nephropathy. We want to see if it can help reduce protein in the urine and protect kidney function compared to a dummy medicine.
Immunoglobulin A NephropathySaudi Arabia - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseSaudi Arabia - Active not recruitingNA
SyncAV Post-Market Trial
This study looks at a special heart device for people with heart failure. We're testing if a new setting, called SyncAV ON, helps the device work better and improve the heart's function more than the usual settings.
Congestive Heart FailureSaudi Arabia - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
Non-small Cell Lung CancerSaudi Arabia - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersSaudi Arabia - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
Chronic Lymphocytic LeukemiaSaudi Arabia - RecruitingPHASE4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
This study looks at how well a medicine called pegcetacoplan works and if it's safe for people in the UK with rare kidney diseases like C3G or IC-MPGN. It uses real-life information from patients to help doctors make better decisions about treatment.
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Saudi Arabia - Active not recruitingPHASE3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study looks at a long-term treatment called nerandomilast for people with pulmonary fibrosis. It's for those who've used it in a past study. We'll see how safe and effective it is over time, checking if it helps lung function and slows down the disease.
Idiopathic Pulmonary FibrosisProgressive Pulmonary FibrosisSaudi Arabia - Active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
Advanced or Metastatic Breast CancerSaudi Arabia - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungSaudi Arabia - RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Saudi Arabia - Active not recruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
Breast Cancer, Early Breast CancerSaudi Arabia - RecruitingPHASE3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.
Focal Segmental GlomerulosclerosisSaudi Arabia - Active not recruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
Multiple MyelomaSaudi Arabia - Active not recruitingPHASE3
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
This study looks at a new, higher dose of macitentan (75mg) for people with pulmonary arterial hypertension (PAH). Researchers want to see if this dose is better than the current 10mg dose at preventing serious health problems or death related to PAH.
Pulmonary Arterial HypertensionSaudi Arabia - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
Heart FailureSaudi Arabia - RecruitingPhase III
A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3-stage metabolic dysfunction-associated steatohepatitis (BOS-580-302)
This clinical study tests a new monthly injection called efimosfermin alfa for adults with MASH, a condition where fat causes liver inflammation and scarring. Doctors want to see if the medicine is safe and well tolerated over 52 weeks compared to a dummy injection (placebo).
Metabolic dysfunction-associated steatohepatitis (MASH)Saudi Arabia - RecruitingPhase II
A phase 2b, open-label, two-cohort study of subcutaneous amivantamab in combination with lazertinib as first-line treatment, or subcutaneous amivantamab in combination with platinum-based chemotherapy as second-line treatment, for common EGFR-mutated locally advanced or metastatic non-small cell lung cancer
This study looks at new drug combinations for a common type of lung cancer called NSCLC, specifically when it has a certain gene change (EGFR mutation). It tests if these new treatments can help reduce or slow down the cancer.
Common EGFR-mutated locally advanced or metastatic non-small cell lung cancerSaudi Arabia - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaSaudi Arabia - Recruiting
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
This study looks at how men with advanced prostate cancer respond to darolutamide and hormone therapy, sometimes with chemotherapy, in real-world settings. It aims to understand treatment effectiveness, safety, and patient experiences to help improve care.
Metastatic Hormone-Sensitive Prostate CancerSaudi Arabia - RecruitingPHASE3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
This study is testing a new medicine, lunsekimig, for adults aged 40-80 with COPD that's not well-controlled. We want to see if it helps improve breathing, is safe, and has manageable side effects compared to a dummy medicine.
Chronic Obstructive Pulmonary DiseaseSaudi Arabia - RecruitingPHASE3
A Gaucher Disease Gene Therapy Trial With FLT201
This study is testing a new gene therapy called FLT201 for adults with Gaucher disease type 1. It aims to see if patients can stop their current treatment after receiving FLT201 while remaining well. This is the final stage of testing before it might become available.
Gaucher Disease Type 1Saudi Arabia